Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Andrew J. Aguirre

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0701-6203; OpenAlex author ID A5079764447; NIH RePORTER profile ID 10995625. Sources: OpenAlex.

Their work

Papers
66 (first author 0, last author 5)
Trials
0
Grants
6
Labs led
1
Collaborators
294
Papers, trials and grants by year

2013: 1 grant · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: 5 papers, 1 grant · 2019: 2 papers · 2020: 5 papers · 2021: 8 papers, 1 grant · 2022: 6 papers · 2023: 8 papers · 2024: 7 papers · 2025: 9 papers · 2026: 14 papers, 3 grants

Papers 50 of 66

  1. CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. Co-author DOI 10.1016/j.cell.2026.08.045↗
  2. GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2026.117314↗
  3. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Co-author DOI 10.1016/j.celrep.2026.117627↗
  4. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Co-author DOI 10.1038/s41591-026-04537-w↗
  5. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Co-author DOI 10.1038/s43018-026-01165-8↗
  6. Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer. Co-author DOI 10.1093/immadv/ltag013↗
  7. Iron overload suppresses LKB1 and induces IL36G anti-tumor immunity in PDAC metastasis. Co-author DOI 10.1126/sciadv.adz8681↗
  8. CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1835↗
  9. Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment. Co-author DOI 10.1158/0008-5472.can-25-1969↗
  10. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Co-author DOI 10.1158/1078-0432.ccr-24-3766↗
  11. Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identification Co-author DOI 10.64898/2026.04.02.26349987↗
  12. Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.08.24.26360900↗
  13. Context-specific genetic interaction mapping reveals combinatorial KRAS/FGFR dependence in pancreatic cancer Co-author DOI 10.64898/2026.09.24.754062↗
  14. KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer Co-author DOI 10.64898/2026.10.01.756025↗
  15. Integrative genomic identification of therapeutic targets for pancreatic cancer. Last author DOI 10.1016/j.celrep.2025.116191↗
  16. De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer. Co-author DOI 10.1038/s41467-025-61242-x↗
  17. Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer. Co-author DOI 10.1038/s41586-025-08927-x↗
  18. Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Co-author DOI 10.1126/science.adk3487↗
  19. Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-3149↗
  20. Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate. Co-author DOI 10.1158/1078-0432.ccr-25-2333↗
  21. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  22. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  23. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  24. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-07379-z↗
  25. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08084-7↗
  26. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  27. Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-1926↗
  28. Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-24-1164↗
  29. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-24-0177↗
  30. Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer. Co-author DOI 10.1200/edbk_438598↗
  31. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Co-author DOI 10.1016/j.xcrm.2023.101007↗
  32. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Co-author DOI 10.1038/s41467-023-40024-3↗
  33. Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-subtype model. Co-author DOI 10.1038/s42003-023-04461-6↗
  34. Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy. Co-author DOI 10.1053/j.gastro.2023.05.038↗
  35. Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad002↗
  36. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  37. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-22-3930↗
  38. A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancr… Co-author DOI 10.1158/1078-0432.ccr-23-2005↗
  39. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Co-author DOI 10.1038/s41588-022-01134-8↗
  40. Translational advances in pancreatic ductal adenocarcinoma therapy. Co-author DOI 10.1038/s43018-022-00349-2↗
  41. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  42. NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron-Sulfur Cluster Proteins. Co-author DOI 10.1158/2159-8290.cd-22-0043↗
  43. Coordinated Transcriptional and Catabolic Programs Support Iron-Dependent Adaptation to RAS-MAPK Pathway Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-0044↗
  44. Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers14246223↗
  45. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.11.017↗
  46. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Co-author DOI 10.1016/j.celrep.2021.109291↗
  47. SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization. Co-author DOI 10.1016/j.celrep.2021.109443↗
  48. Functional Genomics Identifies Metabolic Vulnerabilities in Pancreatic Cancer. Co-author DOI 10.1016/j.cmet.2020.10.018↗
  49. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  50. Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-1367↗

Grants 6

  1. The function of the PRMT5 methylosome in MTAP deleted cancers R01CA233626↗
  2. Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer R01CA276268↗
  3. Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity U01CA274276↗
  4. Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer K08CA218420↗
  5. Functional Genetic Discovery of Novel Targets in Pancreatic Cancer AWARD pancan:2018-andrew-aguirre-md-phd-functional-genetic-discovery-of-novel-ta
  6. Validation of Novel KRAS Synthetic Lethal Targets in Pancreatic Cancer AWARD pancan:2013-andrew-aguirre-md-phd-validation-of-novel-kras-synthetic-letha

Closest collaborators

The 25 strongest of 294 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 33 shared papers, 2018–2026 · strength 4.39
  2. Kimberly J. Perez · 20 shared papers, 2019–2026 · strength 2.85
  3. Harshabad Singh · 18 shared papers, 2021–2026 · strength 2.82
  4. James M. Cleary · 18 shared papers, 2021–2026 · strength 2.64
  5. Jonathan Andrew Nowak · 20 shared papers, 2018–2026 · strength 2.56
  6. Stephanie K. Dougan · 8 shared papers, 1 shared grant, 2021–2026 · strength 2.50
  7. Douglas Adam Rubinson · 19 shared papers, 2018–2026 · strength 2.29
  8. Srivatsan Raghavan · 15 shared papers, 2018–2026 · strength 1.97
  9. William C. Hahn · 9 shared papers, 1 shared grant, 2018–2026 · strength 1.89
  10. Joseph Douglas Mancias · 10 shared papers, 2022–2026 · strength 1.59
  11. William R Sellers · 1 shared paper, 1 shared grant, 2026 · strength 1.48
  12. Kimmie Ng · 12 shared papers, 2018–2026 · strength 1.44
  13. Brandon M. Huffman · 8 shared papers, 2021–2026 · strength 1.26
  14. Chen Yuan · 11 shared papers, 2018–2024 · strength 1.13
  15. Anirban Maitra · 5 shared papers, 2022–2026 · strength 1.07
  16. Thomas E. Clancy · 10 shared papers, 2018–2026 · strength 1.02
  17. Andressa Dias Costa · 8 shared papers, 2020–2026 · strength 0.98
  18. Julien Dilly · 5 shared papers, 2023–2026 · strength 0.92
  19. Matthew B.B. Yurgelun · 7 shared papers, 2019–2026 · strength 0.90
  20. Channing J. Der · 6 shared papers, 2020–2026 · strength 0.79
  21. Geoffrey Ira Shapiro · 6 shared papers, 2021–2026 · strength 0.76
  22. Rishi Surana · 5 shared papers, 2022–2026 · strength 0.75
  23. Brendan D. Parent · 3 shared papers, 2026 · strength 0.75
  24. Hannah L. Williams · 6 shared papers, 2021–2025 · strength 0.70
  25. Clint A. Stalnecker · 4 shared papers, 2021–2026 · strength 0.69

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.